Silexion Therapeutics Corp SLXN
Set alert
0.16 USD +0.01 +6.68%
As of Nov 3, 9:45 AM ET
0.1493 Day range 0.1582
0.14 52-week range 32.38
- YTD
- -99.18%
- 1 year
- -99.50%
- Open
- 0.1493
- Prev close
- 0.1483
- Mkt cap
- 2.41M
- Vol
- 27.82K
- Avg vol
- 10.26M
- EPS
- -27.21
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.1493
- High
- 0.1582
- Forward P/E
- -3.95
- Beta
- -0.11
- Short ratio
- 0.23
- Inst. own
- 8.15%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.12
- 200-d avg
- 6.82
- 1y target
- 9.00
2Y chart
Events in this range
- Nov 14, 2024Earnings: -18.27; estimate 0; surprise —%
- May 29, 2026Split: 1 for 10
Signals (68)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 16, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 12, 2026 | 3 weeks ago |
| MACD: Buy Signal | Aug 26, 2026 | 2 months ago |
| RSI: Oversold | Aug 11, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 10, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 7, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 30, 2026 | 3 months ago |
| RSI: Oversold | Jul 29, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 23, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 15, 2026 | 4 months ago |
| MACD: Buy Signal | May 20, 2026 | 5 months ago |
| MACD: Sell Signal | May 15, 2026 | 5 months ago |
| MACD: Buy Signal | May 12, 2026 | 5 months ago |
| MACD: Sell Signal | Apr 24, 2026 | 6 months ago |
| RSI: Oversold | Apr 24, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 17, 2026 | 6 months ago |
| RSI: Oversold | Apr 13, 2026 | 6 months ago |
| RSI: Oversold | Mar 20, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 17, 2026 | 7 months ago |
| SMA: Bearish | Mar 12, 2026 | 7 months ago |
Newest 20 of 68.
Key statistics
- Market cap
- 4.06M
- Enterprise value
- 16.46M
- Trailing P/E
- 0.00
- Forward P/E
- -3.95
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.54
- EPS (TTM)
- -13.22
- Beta
- -0.11
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -305.63K
- Total cash
- 2.78M
- Total debt
- 144.00K
- Return on equity
- -116.66%
- Shares outstanding
- 1.60M
- Short % of float
- 3.08%
- 50-day average
- 1.12
- 200-day average
- 6.82
Analyst view
Consensus: buy
Buy
Price target (mean) 9.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
SLXN Revenue — quarterly 0
SLXN Net income — quarterly -3.55M
SLXN EPS — quarterly -5.17
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -18.27 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 1, 2024 | Maxim Group | init | — | Buy |
About Silexion Therapeutics Corp
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- silexion.com
News
- 12 Health Care Stocks Moving In Friday's After-Market Session
- 12 Health Care Stocks Moving In Friday's After-Market Session
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Silexion Therapeutics Announces First Patient Dosed Phase 2/3 Clinical Trial Evaluating Lead Candidate, SIL204, In Patients With Locally Advanced Pancreatic Cancer
- Why FingerMotion Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- Silexion Therapeutics To Raise $837K Via Exercise Of ~3.217M Series E Warrants At $0.2603/Share
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Why Navitas Semiconductor Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
- Silexion Therapeutics (SLXN) Stock Soars 61% After Hours: Here's What's Going On
Your note
Sign in to keep a note on SLXN — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Wildcat Capital Management, LLC | 0.79% | 113,428 | 286.97K | Sep 29, 2024 |
| HRT Financial LP | 0.07% | 9,997 | 25.29K | Sep 29, 2024 |
| Virtu Financial LLC | 0.02% | 2,962 | 7.49K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 0.01% | 1,680 | 4.25K | Sep 29, 2024 |
| UBS Group AG | 0.01% | 1,673 | 4.23K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.00% | 587 | 1.49K | Oct 30, 2024 |